



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Elsilimomab

Cat. No.:	HY-P99287
CAS No.:	468715-71-1
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a K_D of 22 pM and an IC_{50} of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) ^{[1][2][3]} .									
IC₅₀ & Target	IL-6 1.4 nM (IC_{50})									
In Vitro	<p>Elsilimomab specifically inhibits IL-6 but not LIF (leukemia inhibitory factor)-induced cell growth^[2]. Elsilimomab (20 µg/mL) neutralizes human IL-6^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Murine B9 cells</td> </tr> <tr> <td>Concentration:</td> <td>20 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>3 days</td> </tr> <tr> <td>Result:</td> <td>B9 cells were stimulated with human IL-6, which was effectively neutralized by antibody Elsilimomab.</td> </tr> </table>		Cell Line:	Murine B9 cells	Concentration:	20 µg/mL	Incubation Time:	3 days	Result:	B9 cells were stimulated with human IL-6, which was effectively neutralized by antibody Elsilimomab.
Cell Line:	Murine B9 cells									
Concentration:	20 µg/mL									
Incubation Time:	3 days									
Result:	B9 cells were stimulated with human IL-6, which was effectively neutralized by antibody Elsilimomab.									

REFERENCES

- [1]. Lee JJ, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. *Mol Ther.* 2014 Jul;22(7):1254-1265.
- [2]. Burger R, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. *Haematologica.* 2017 Feb;102(2):381-390.
- [3]. Finch DK, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. *J Mol Biol.* 2011 Aug 26;411(4):791-807.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA